Cancer treatment reviews · 2026
Circulating tumor DNA for predicting recurrence and mortality in patients with resected Melanoma: A systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abrahão Reis Pedro C, Noronha Mariana Macambira, Oliveira João Pedro, Ponte Conrado João Evangelista, Buonopane Isabella Romagnoli, Holanda Lopes Carlos Diego, Araujo Daniel V, Saldanha Erick F
Аннотация
BACKGROUND: Resectable melanoma remains associated with substantial relapse risk despite adjuvant therapy, and prognostic biomarkers for better risk stratification are urgently needed. We evaluated the prognostic and diagnostic performance of circulating tumor DNA (ctDNA) in patients with resectable melanoma.
METHODS: PubMed, Embase, and Cochrane databases were systematically searched through July 2025 for studies evaluating ctDNA detection in patients with resected melanoma and reporting outcomes of interest. All ctDNA data were assessed at three timepoints: baseline (pre-surgery), landmark (≤12 weeks post-surgery), and longitudinal surveillance. Random-effects models estimated hazard ratios (HR) with 95% confidence intervals (CI) for relapse-free survival (RFS), distant metastasis-free survival (DMFS), and overall survival (OS). Diagnostic performance was evaluated using both univariate and bivariate models.
RESULTS: Twenty-four cohorts comprising 3,032 patients were included, with a median follow-up of 38.5 months. Baseline ctDNA positivity was associated with worse RFS (HR 3.14; 95% CI 1.82-5.41) and DMFS (HR 2.25; 95% CI 1.50-3.36), but not OS. At the landmark timepoint, ctDNA positivity predicted worse RFS (HR 3.42; 95% CI 2.51-4.65), DMFS (HR 5.38; 95% CI 3.09-9.37), and OS (HR 3.55; 95% CI 2.63-4.79). Longitudinal ctDNA detection showed the strongest prognostic association with RFS (HR 3.76; 95% CI 2.83-4.99). Diagnostic performance demonstrated modest sensitivity (31-53%) but high specificity (>90%) at landmark and longitudinal timepoints, with no significant differences in accuracy between these timepoints.
CONCLUSION: Detectable ctDNA in resectable cutaneous melanoma is a negative prognostic marker associated with significantly higher rates of relapse, distant metastasis, and mortality. Diagnostic metrics revealed that plasma ctDNA has high specificity with suboptimal sensitivity.
METHODS: PubMed, Embase, and Cochrane databases were systematically searched through July 2025 for studies evaluating ctDNA detection in patients with resected melanoma and reporting outcomes of interest. All ctDNA data were assessed at three timepoints: baseline (pre-surgery), landmark (≤12 weeks post-surgery), and longitudinal surveillance. Random-effects models estimated hazard ratios (HR) with 95% confidence intervals (CI) for relapse-free survival (RFS), distant metastasis-free survival (DMFS), and overall survival (OS). Diagnostic performance was evaluated using both univariate and bivariate models.
RESULTS: Twenty-four cohorts comprising 3,032 patients were included, with a median follow-up of 38.5 months. Baseline ctDNA positivity was associated with worse RFS (HR 3.14; 95% CI 1.82-5.41) and DMFS (HR 2.25; 95% CI 1.50-3.36), but not OS. At the landmark timepoint, ctDNA positivity predicted worse RFS (HR 3.42; 95% CI 2.51-4.65), DMFS (HR 5.38; 95% CI 3.09-9.37), and OS (HR 3.55; 95% CI 2.63-4.79). Longitudinal ctDNA detection showed the strongest prognostic association with RFS (HR 3.76; 95% CI 2.83-4.99). Diagnostic performance demonstrated modest sensitivity (31-53%) but high specificity (>90%) at landmark and longitudinal timepoints, with no significant differences in accuracy between these timepoints.
CONCLUSION: Detectable ctDNA in resectable cutaneous melanoma is a negative prognostic marker associated with significantly higher rates of relapse, distant metastasis, and mortality. Diagnostic metrics revealed that plasma ctDNA has high specificity with suboptimal sensitivity.